Search SS-31 before and after and you get physique shots and skin shots. The published record contains no photographs at all. What it contains is a 6-minute walk test in patients with Barth syndrome.
The short answer. No trial of SS-31 used a photograph as an endpoint; the measures were walk distance, strength, and symptom scales.
- TAZPOWER's randomized phase showed 25.2 m versus 2.0 m on the 6-minute walk and missed significance; the approval leaned on a 168-week extension in 8 patients.
- MMPOWER-3 missed both primary endpoints over 24 weeks in primary mitochondrial myopathy; the genotype subgroup finding was post hoc.
- In aged mice, Aging Cell reported better heart and muscle function with no detectable change in epigenetic or transcriptomic age.
SS-31 is elamipretide. The FDA approved it in September 2025. The approved use is Barth syndrome, a very rare disease. Trials measured walking distance and muscle strength, not photos. Long-term data covers 8 patients over 168 weeks. Anti-aging claims rest on aged mice.
What SS-31 before and after actually measured
Every endpoint in the elamipretide program is a number, not an image. Patients walked for six minutes and somebody measured the distance. Patients pushed against a dynamometer and somebody measured the force. Patients and parents filled in symptom scales.
No trial photographed anyone. No trial ran DEXA, skin imaging, or body composition. So a before-and-after picture attached to this compound is not a trial result that leaked out. It is a separate thing with no published counterpart.
| Study | Who | Length | What was measured |
|---|---|---|---|
| TAZPOWER, randomized phase | Barth syndrome, about 10 patients | 28 weeks | 6-minute walk distance; symptom scale |
| TAZPOWER open-label extension | 8 patients | 168 weeks | Walk distance, muscle strength, safety |
| MMPOWER-3 | Primary mitochondrial myopathy | 24 weeks | 6-minute walk distance; symptom score |
| Aging Cell 2025 | Aged mice | Not applicable | Heart and muscle function; epigenetic age |
That is the whole measured record. The chemistry behind it is covered in the cardiolipin mechanism page.
The TAZPOWER numbers, in full
TAZPOWER is the trial behind the approval. It was a crossover study in Barth syndrome, an X-linked disorder that the Orphanet review places at roughly 1 in 300,000–400,000 male births.
In the randomized 28 weeks, walk distance moved 25.2 m on elamipretide against 2.0 m on placebo. That gap did not reach statistical significance. The primary endpoint was missed.
The approval did not come from that randomized window. It came from what happened after, when patients stayed on drug in an open-label extension that ran 168 weeks in 8 people. Eight people is the entire long-term human dataset.
Elamipretide is approved in the USA for the treatment of Barth syndrome in patients weighing at least 30 kg.
Shirley, Drugs, 2025, “Elamipretide: First Approval”The label is narrow on purpose. It names a weight floor of 30 kg and one genetic disease. The full regulatory story sits on the Barth syndrome FDA page.
The larger trial, and why it failed
Before Barth syndrome, the same compound was tested in a much bigger population: primary mitochondrial myopathy. That trial was MMPOWER-3, published in Neurology by Karaa and colleagues in 2023.
It ran 24 weeks. It missed. Walk distance and the symptom score both failed to separate from placebo in the overall group.
Elamipretide did not meet the primary endpoints of change in 6-minute walk test distance or change in the mitochondrial myopathy symptom assessment.
Karaa et al., Neurology, 2023 (MMPOWER-3 conclusion)A 2024 post hoc analysis in Orphanet Journal of Rare Diseases went back through the data by genotype. In one genetic subgroup the separation was large, around 37.3 m against -8.0 m. That is an exploratory finding generated after the trial read out, not a result the trial was designed to produce.
So the honest summary is a split one. In a rare disease defined by one gene, the compound cleared a regulatory bar on tiny numbers. In the broader mitochondrial disease population, it did not.
Does SS-31 reverse aging in any measured way?
This is where most of the before-and-after search traffic actually comes from, and the best study on it is in mice.
Mitchell and colleagues published in Aging Cell in 2025. Aged mice given elamipretide showed better heart and skeletal muscle function. Then the authors checked whether the tissue itself had gotten biologically younger.
Improves cardiac and skeletal muscle function during aging without detectable changes in tissue epigenetic or transcriptomic age.
Mitchell et al., Aging Cell, 2025 (paper title)Function improved. The clock did not move. Those are two different claims, and the marketing collapses them into one.
There is no controlled trial of SS-31 in healthy adults for aging, body composition, skin, or athletic output. The count is zero. The benefits page goes through claim by claim.
What has never been measured at all
It helps to list the gaps plainly, because they are what a photograph is standing in for.
- No body composition data. No DEXA, no fat mass, no lean mass endpoint in any published human trial.
- No skin or cosmetic endpoint. The retinal literature discusses mitochondrial targeting in macular disease, but that is an eye endpoint, not a face.
- No healthy-volunteer efficacy trial. Every efficacy dataset comes from genetic disease.
- No oral data. The peptide is a four-amino-acid sequence of about ~640 g/mol, and the trials used injection.
There is also a price gap worth noticing. The approved drug has been reported at $300,000 to $750,000 a year. A research vial is not that product, was not made under the same controls, and carries none of the same testing.
For the other mitochondrial peptide people compare it to, see SS-31 vs MOTS-c. MOTS-c is a 16-amino-acid peptide with no human trials either.
How to read a vendor before-and-after
A photo pair tells you nothing about identity, purity, or whether the vial held what the label said. Documents do.
- Ask what the analysis certificate actually shows. Batch number, test date, method, and purity. How to read a COA covers the common dodges.
- Check the storage claim. Peptide stability is temperature dependent and shipping is the weak link. See storage temperature.
- Know the legal framing. Research-use material is not an approved medicine. Are peptides legal sets out the distinction.
And compare the photo against the measured scale. The largest documented human change for this compound is tens of meters on a walk test, in people with a genetic mitochondrial disease. That is a meaningful result for them. It is not a visual transformation.
The full development history is in the SS-31 complete guide.
What to know now
- No trial of SS-31 used a photograph as an endpoint; the measures were walk distance, strength, and symptom scales.
- TAZPOWER's randomized phase showed 25.2 m versus 2.0 m on the 6-minute walk and missed significance; the approval leaned on a 168-week extension in 8 patients.
- MMPOWER-3 missed both primary endpoints over 24 weeks in primary mitochondrial myopathy; the genotype subgroup finding was post hoc.
- In aged mice, Aging Cell reported better heart and muscle function with no detectable change in epigenetic or transcriptomic age.
- There is no controlled human trial of SS-31 for aging, body composition, or skin.
- A research vial is not the approved drug Forzinity and carries none of its testing.
What we're watching
elamipretide TAZPOWER Barth syndrome trial results explained
Frequently asked questions
Are there any SS-31 before and after photos in the published studies?
No. Every published elamipretide study used numeric endpoints: 6-minute walk distance, muscle strength, symptom questionnaires, and safety labs. No trial published patient photographs or body composition imaging. Any before-and-after image you find online sits outside the research record.
How long did the trials run before anything changed?
This is reporting, not guidance. The TAZPOWER randomized phase ran 28 weeks and its walk-test difference was not statistically significant. The open-label extension ran 168 weeks in 8 patients. MMPOWER-3 ran 24 weeks and missed its primary endpoints.
Does SS-31 build muscle or reduce body fat?
Nothing published supports that in humans. The muscle endpoints in the trials were function tests in patients with genetic mitochondrial disease, not hypertrophy. No human trial has measured fat mass or lean mass with this compound.
Is research SS-31 the same as the FDA-approved Forzinity?
They share a molecule name, elamipretide, but not a status. Forzinity is an approved product for Barth syndrome in patients weighing at least 30 kg, manufactured and tested to pharmaceutical standards. A research vial is sold for laboratory use, with purity you have to verify from a certificate of analysis.
Did the mouse aging study show age reversal?
Not by the measures the authors used. Mitchell and colleagues reported improved cardiac and skeletal muscle function in aged mice, then stated the tissue showed no detectable change in epigenetic or transcriptomic age. Better function is not the same as a younger biological clock.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about Ss 31 deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
These are uncontrolled, unverified self-reports, not trial data. The recurring claim across them is fast energy and sharper thinking, sometimes within days. The one long first-person log, from a housebound ME/CFS poster, describes a dose response that does not run in one direction: the smallest amount read as stimulating and "Stronger than caffeine", the largest as so sedating he was "Sleeping 14-16 hrs per day". A YouTube commenter under the same-titled review says a lower amount suits him better than a higher one. Constipation and insomnia recur inside that log, and replies under it describe hives bad enough that one commenter stopped: "Both gave me hives. I can't take them anymore." The dissent is loud. One ME/CFS commenter says he gave it an adequate dose over ten days and got nothing. A r/Biohackers poster says SS-31 made her fatigue worse until she added supplements, though her own later updates to that post say it ended up helping. Note who is talking: the most enthusiastic thread in this set opens with a pitch and links to a vendor referral URL, and the negative report sits in its comments.
Where the community and the published record disagree. The community treats SS-31 as a fatigue peptide for people whose mitochondrial problem is assumed rather than measured, yet the controlled trial in patients with genetically confirmed primary mitochondrial myopathy, MMPOWER-3, missed its primary endpoints (Neurology 2023, PMID 37268435): 218 randomized, and the difference from placebo on the 6-minute walk test was -3.2 meters (95% CI -18.7 to 12.3; p = 0.69). The only FDA approval, Forzinity (NDA215244, Stealth Biotherapeutics, approved 2025-09-19), is an accelerated approval in Barth syndrome resting on an improvement in knee extensor muscle strength, which the label itself calls "an intermediate clinical endpoint", at 40 mg subcutaneously once daily, an amount far above what most posters describe using. The same label states that in its randomized trial "FORZINITY was not superior to placebo on these primary endpoints", and that the strength increases "were not observed during the randomized trial but were observed during the extension period", which was open-label and single-arm.
“SS-31 has been the single most effective treatment I have tried for improving energy.”
My Experience Treating my ME/CFS with mitochondrial peptide SS-31
“I tried SS-31 and it did jack shit for me.”
“I definitely could tell that I took something, but over the day, I actually lost energy.”
Peptide SS-31 caused me more fatigue until I added methyl donors (B12, TMG & NAD+) to fix it
“I’ve felt nothing but fatigue and shocking workout recovery”
“During my first round of SS-31 research, I experienced cleaner energy, improved recovery, better endurance, reduced fatigue, and more stable focus.”
SS-31 Before vs After MOTS-c | Massive Difference in Results
“it is hard to explain, we had energy but not like drinking coffee if that makes any sense.”
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Shirley, M. (2025). Elamipretide: First Approval. Drugs, 86(3), 377–383. https://doi.org/10.1007/s40265-025-02269-8
- Karaa, A., Haas, R., Goldstein, A., Vockley, J., & Cohen, B. (2023). Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: The MMPOWER-3 randomized clinical trial. Neurology. https://doi.org/10.1212/WNL.0000000000207402
- Karaa, A., Bertini, E., Carelli, V., et al. (2024). Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: A post hoc analysis of the MMPOWER-3 trial. Orphanet Journal of Rare Diseases, 19(1), 431. https://doi.org/10.1186/s13023-024-03421-5
- Stealth BioTherapeutics. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. https://doi.org/10.1016/j.gim.2024.101138
- Mitchell, W., Pharaoh, G., Tyshkovskiy, A., et al. (2025). The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell, 24(6), e70026. https://doi.org/10.1111/acel.70026
- Tung, C., Varzideh, F., Farroni, E., et al. (2025). Elamipretide: A review of its structure, mechanism of action, and therapeutic potential. International Journal of Molecular Sciences, 26(3), 944. https://doi.org/10.3390/ijms26030944
- Clarke, S. L. N., Bowron, A., Gonzalez, I. L., et al. (2013). Barth syndrome. Orphanet Journal of Rare Diseases, 8, 23. https://doi.org/10.1186/1750-1172-8-23
- Obi, C., Smith, A. T., Hughes, G. J., & Adeboye, A. A. (2022). Targeting mitochondrial dysfunction with elamipretide. Heart Failure Reviews, 27(5), 1925–1932. https://doi.org/10.1007/s10741-021-10199-2
- Nashine, S. (2021). Potential therapeutic candidates for age-related macular degeneration (AMD). Cells, 10(9), 2483. https://doi.org/10.3390/cells10092483
